Literature DB >> 27602589

Identification of dual ligands targeting angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ by core hopping of telmisartan.

Jun Zhang1, Xin Liu1, Shu-Qing Wang1, Gui-You Liu1, Wei-Ren Xu2, Xian-Chao Cheng1, Run-Ling Wang1.   

Abstract

It has been reported previously that some angiotensin II receptor blockers not only antagonize angiotensin II type 1 receptor (AT1R), but also exert stimulation in peroxisome proliferator-activated receptor γ (PPARγ) partial activation, among which telmisartan displays the best. Telmisartan has been tested as a bifunctional ligand with antihypertensive and hypoglycemic activity. Aiming at more potent leads with selective AT1R antagonism and PPARγ partial agonism, the three parts of telmisartan including the distal benzimidazole ring, the biphenyl moiety, and the carboxylic acid group experienced modification by core hopping method in our study. The central benzimidazole ring, however, remained intact considering its great affinity toward AT1R and PPARγ. We utilized computational techniques for the sake of details on the binding interactions and conformational stability. Standard precision docking analysis and absorption, distribution, metabolism, excretion, and toxicity prediction received 10 molecules with higher Glide scores, similar interactions, and improved pharmacokinetic profiles compared to telmisartan. Comp#91 with highest scores for AT1R (-11.92 kcal/mol) and PPARγ (-13.88 kcal/mol) exhibited excellent binding modes and pharmacokinetic parameters. Molecular dynamics trajectories on best docking pose of comp#91 confirmed the docking results and verified the conformational stability with both receptors throughout the course of 20-ns simulations. Thus, comp#91 could be identified as a promising lead in the development of dual AT1R antagonist and PPARγ partial agonist against hypertension and type 2 diabetes.

Entities:  

Keywords:  ADMET; AT1R; PPARγ; SP docking; molecular dynamics; telmisartan

Mesh:

Substances:

Year:  2016        PMID: 27602589     DOI: 10.1080/07391102.2016.1227726

Source DB:  PubMed          Journal:  J Biomol Struct Dyn        ISSN: 0739-1102


  4 in total

Review 1.  MAPK signaling pathway-targeted marine compounds in cancer therapy.

Authors:  Jiaen Wei; Ruining Liu; Xiyun Hu; Tingen Liang; Zhiran Zhou; Zunnan Huang
Journal:  J Cancer Res Clin Oncol       Date:  2021-01-03       Impact factor: 4.553

Review 2.  The endocannabinoid system in cardiovascular function: novel insights and clinical implications.

Authors:  Salvador Sierra; Natasha Luquin; Judith Navarro-Otano
Journal:  Clin Auton Res       Date:  2017-12-08       Impact factor: 4.435

3.  Design, Synthesis, Molecular Docking Analysis and Biological Evaluations of 4-[(Quinolin-4-yl)amino]benzamide Derivatives as Novel Anti-Influenza Virus Agents.

Authors:  Chao Zhang; Yun-Sang Tang; Chu-Ren Meng; Jing Xu; De-Liang Zhang; Jian Wang; Er-Fang Huang; Pang-Chui Shaw; Chun Hu
Journal:  Int J Mol Sci       Date:  2022-06-04       Impact factor: 6.208

Review 4.  Hypertension and its management in COVID-19 patients: The assorted view.

Authors:  Gaber El-Saber Batiha; Abdulrahim Gari; Norhan Elshony; Hazem M Shaheen; Murtala Bello Abubakar; Sherif Babatunde Adeyemi; Hayder M Al-Kuraishy
Journal:  Int J Cardiol Cardiovasc Risk Prev       Date:  2021-11-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.